Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2651-2656

  Gu, Xiaobin ^a,b,c   Tian, Tian ^a,b,c   Zhang, Bo ^a,b,c   Liu, Yang ^a,b,c   Yuan, Chao ^a,b,c   Shao, Lijuan ^a,b,c   Guo, Yajun ^a,b,c   Fan, Kexing ^a,b,c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

IL 35; Non small cell lung cancer; Prognosis; Tumor marker

Indexed keywords

INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; TUMOR MARKER;

ADULT; AGED; BLOOD; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84936772254     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2887-8     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Canc J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.
2. Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S, Kochupillai V. Non small cell lung cancer (NSCLC): current status and future prospects. Indian J Chest Dis Allied Sci. 2004;46(3):191–203.
3. Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Canc Cell. 2012;21(3):448.e2. doi:10.1016/j.ccr.2012.03.007.
4. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol Offic J Am Soc Clin Oncol. 1995;13(5):1221–30.
5. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566–U19. doi:10.1038/nature06306.
6. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA. 1997;94(22):12041–6. doi:10.1073/pnas.94.22.12041.
7. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37(11):3021–9. doi:10.1002/eji.2007378101.
8. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11(12):1093–U97. doi:10.1038/ni.1952.
9. Wang ZH, Liu JQ, Liu ZZ, Shen RL, Zhang GQ, Xu JP, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 2013;190(5):2415–23. doi:10.4049/jimmunol.1202535.
10. Shen P, Roch T, Lampropoulou V, O’Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366–70. doi:10.1038/nature12979.
11. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48. doi:10.1016/j.immuni.2004.07.017.
12. Devergne O, Coulomb-L’Hermine A, Capel F, Moussa M, Capron F. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol. 2001;159(5):1763–76. doi:10.1016/s0002-9440(10)63023-4.
13. Poleganov MA, Bachmann M, Pfeilschifter J, Muhl H. Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor. Mol Immunol. 2008;45(10):2869–80. doi:10.1016/j.molimm.2008.01.021.
14. Niedobitek G, Pazolt D, Teichmann M, Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol. 2002;198(3):310–6. doi:10.1002/path.1217.
15. Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, et al. Identification of Epstein-Barr virus-induced gene 3 as a novel plasma and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011;17(19):6272–86. doi:10.1158/1078-0432.ccr-11-0060.
16. Jin P, Ren H, Sun W, Xin W, Zhang H, Hao JH. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol. 2014;75(1):29–33. doi:10.1016/j.humimm.2013.09.018.
17. Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 2013;6(9):1806–16.
18. Wu H, Li P, Shao N, Ma J, Ji M, Sun X, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. Oncol Lett. 2012;3(5):1119–23. doi:10.3892/ol.2012.614.
19. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(6):645–53. quiz 53.
20. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010;184(12):7144–53. doi:10.4049/jimmunol.0902739.
21. Long J, Zhang XL, Wen MJ, Kong QL, Lv Z, An YQ, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun. 2013;430(1):364–9. doi:10.1016/j.bbrc.2012.11.004.